328 related articles for article (PubMed ID: 15028666)
1. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
2. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.
Mohr PG; Deng YM; McKimm-Breschkin JL
Virol J; 2015 Apr; 12():67. PubMed ID: 25896455
[TBL] [Abstract][Full Text] [Related]
3. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Bauer K; Dürrwald R; Schlegel M; Pfarr K; Topf D; Wiesener N; Dahse HM; Wutzler P; Schmidtke M
Med Microbiol Immunol; 2012 Feb; 201(1):61-72. PubMed ID: 21688167
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
8. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
11. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.
Abed Y; Bourgault AM; Fenton RJ; Morley PJ; Gower D; Owens IJ; Tisdale M; Boivin G
J Infect Dis; 2002 Oct; 186(8):1074-80. PubMed ID: 12355356
[TBL] [Abstract][Full Text] [Related]
12. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
[TBL] [Abstract][Full Text] [Related]
13. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro.
Baigent SJ; Bethell RC; McCauley JW
Virology; 1999 Oct; 263(2):323-38. PubMed ID: 10544106
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
[TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Govorkova EA; Fang HB; Tan M; Webster RG
Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
[TBL] [Abstract][Full Text] [Related]
17. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
19. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
20. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.
Barnett JM; Cadman A; Burrell FM; Madar SH; Lewis AP; Tisdale M; Bethell R
Virology; 1999 Dec; 265(2):286-95. PubMed ID: 10600600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
